Trial Profile
Intravitreal aflibercept injection for exudative age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Mar 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 30 Mar 2017 New trial record
- 01 Jan 2017 Status changed from not yet recruiting to completed.